FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like Japanese Pharma Giant Astellas Sets Up Shop in Cambridge July 24, 2017 NIH Director to Keep Job Under for Now January 19, 2017 Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks October 10, 2017
